Pramipexole safely replaces ergot dopamine agonists with either rapid or slow switching

Journal of International Medical Research

Volumn 36, Issue 1, 2008, Pages 106-114

  Takahashi, Hirohide ^a   Nogawa, S ^b   Tachibana, H ^c   Kawamura, J ^d   Abe, T ^e   Ogino, Y ^f   Kashihara, K ^g   Hamada, T ^h   Kowa, H ^f  

^a TOKAI UNIVERSITY   (Japan)

^b TOKYO DENTAL COLLEGE   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d Okanami General Hospital   (Japan)

^e Abe Neurological Clinic   (Japan)

^f KITASATO UNIVERSITY   (Japan)

^g OKAYAMA KYOKUTO HOSPITAL   (Japan)

^h Hokuyukai Hospital   (Japan)

Author keywords

Dopamine agonists; Parkinson's disease; Pramipexole; Sleepness; Switching study

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PRAMIPEXOLE;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HALLUCINATION; HEADACHE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; NIGHTMARE; OUTCOME ASSESSMENT; PARESTHESIA; PARKINSON DISEASE; PERIPHERAL EDEMA; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; VOMITING;

EID: 39149139011     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600114     Document Type: Article

References (21)

1. Olanow CW, Watts RL, Koller WC: An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001; 56(suppl 5): S1-S88.
2. Reichmann H, Her-ting B, Müller A, et al: Switching and combining dopamine agonists. J Neural Transm 2003; 110: 1393-1400.
3. Kuniyoshi S, Jankovic J: Dopamine agonists in Parkinson's disease. In: Parkinson's Disease (Ebadi M, Pfeifer R, eds). Danvers, MA: CRC Press, 2004; pp 729-744.
4. Van Camp G, Flamez A, Cosyns B, et al: Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology 2003; 61: 859-861.
5. Yamamoto M, Uesugi T, Nakayama T: Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case control study. Neurology 2006; 67: 1225-1229.
6. 3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol 1998; 21: 141-151.
7. Hubble JP, Koller WC, Cutler NR, et al: Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995; 18: 338-347.
8. Parkinson Study Group: Safety and efficacy of pramipexole in early Parkinson's disease, a randomized dose-ranging study. JAMA 1997; 278: 125-130.
9. Shannon KM, Bennett JP Jr, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997; 49: 724-728.
10. Pinter MM, Pogarell O, Oertel WH: Efficacy, safety, and tolerance of the nonergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double-blind, placebo controlled, randomized, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436-441.
11. Lieberman A, Ranhosky A, Korts D: Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double blind, placebo-controlled, parallel-group study. Neurology 1997; 49: 162-168.
12. Mizuno Y, Yanagisawa N, Kuno S, et al: Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 2003; 18: 1149-1156.
13. Schade R, Andersohn F, Suissa S, et al: Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007; 356: 29-38.
14. Goetz CG, Blasucci L, Stebbins GT: Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? Neurology 1999; 52: 1227-1229.
15. Linazasoro G on behalf of the Spanish Dopamine Agonists Study Group: Conversion from dopamine agonists to pramipexole: an open-label trial in 227 patients with advanced Parkinson's disease. J Neurol 2004; 251: 335-339.
16. Grosset K, Needleman F, Macphee G, et al: Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table. Mov Disord 2004; 19: 1370-1374.
17. Tandberg E, Larsen JP, Karlsen K: Community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 1998; 13: 895-899.
18. Frucht S, Rogers JD, Greene PE, et al: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-2010.
19. Ondo WG, Dat Vuong K, Khan H, et al: Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392-1396.
20. Hobson DE, Lang AE, Martin WRW, et al: Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA 2002; 287: 455-463.
21. Paus S, Brecht HM, Köster J, et al: Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659-667.